Literature DB >> 32969192

Image-guided percutaneous microwave ablation of early-stage non-small cell lung cancer.

Yang Ni1, Hui Xu2, Xin Ye2.   

Abstract

Although surgical lobectomy with systematic mediastinal lymph node evaluation is considered as the "gold standard" for management of early stage non-small cell lung cancer (NSCLC), image-guided percutaneous thermal ablation has been increasingly used for medically inoperable patients. Radiofrequency ablation (RFA) is a research-based technique that has the most studies for medically inoperable early-stage NSCLC. Other thermal ablation techniques used to treat pulmonary tumors include microwave ablation (MWA), cryoablation and laser ablation. MWA has several advantages over RFA including reduced procedural time, reduced heat-sink effect, large ablation zones, decreased susceptibility to tissue impedance, and simultaneous use of multiple antennae. This review article highlights the most relevant updates of MWA for the treatment of early-stage NSCLC, including mechanism of action, clinical outcomes, potential complications, the existing technique problems and future directions.
© 2020 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  early stage; microwave ablation; non-small cell lung cancer

Mesh:

Year:  2020        PMID: 32969192     DOI: 10.1111/ajco.13419

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  9 in total

Review 1.  Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer.

Authors:  Chi-Lu Chiang; Ping-Chung Tsai; Yi-Chen Yeh; Yuan-Hung Wu; Han-Shui Hsu; Yuh-Min Chen
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

2.  Assessment and Prognostic Value of Immediate Changes in Post-Ablation Intratumor Density Heterogeneity of Pulmonary Tumors via Radiomics-Based Computed Tomography Features.

Authors:  Bo Liu; Chunhai Li; Xiaorong Sun; Wei Zhou; Jing Sun; Hong Liu; Shuying Li; Haipeng Jia; Ligang Xing; Xinzhe Dong
Journal:  Front Oncol       Date:  2021-11-03       Impact factor: 6.244

3.  Microwave ablation via a flexible catheter for the treatment of nonsurgical peripheral lung cancer: A pilot study.

Authors:  Fangfang Xie; Junxiang Chen; Yifeng Jiang; Jiayuan Sun; D Kyle Hogarth; Felix J F Herth
Journal:  Thorac Cancer       Date:  2022-02-14       Impact factor: 3.500

4.  The correlation between multimodal radiomics and pathology about thermal ablation lesion of rabbit lung VX2 tumor.

Authors:  Jin Chen; Yuan Yan; QingFeng Lin; Jian Chen; Jie Chen; ZhengYu Lin
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

5.  Local ablation of pulmonary malignancies abutting pleura: Evaluation of midterm local efficacy and safety.

Authors:  Hong-Tao Hu; Xiao-Hui Zhao; Chen-Yang Guo; Quan-Jun Yao; Xiang Geng; Wen-Bo Zhu; Hong-Le Li; Wei-Jun Fan; Hai-Liang Li
Journal:  Front Oncol       Date:  2022-08-22       Impact factor: 5.738

6.  Microwave ablation therapy assisted by artificial pneumothorax and artificial hydrothorax for lung cancer adjacent to the vital organs.

Authors:  Jian Chen; Liqin Qi; Jin Chen; Qingfeng Lin; Yuan Yan; Jie Chen; Zhengyu Lin
Journal:  Front Oncol       Date:  2022-08-23       Impact factor: 5.738

7.  Safety and efficacy of microwave ablation for lung cancer adjacent to the interlobar fissure.

Authors:  Nan Wang; Jingwen Xu; Gang Wang; Guoliang Xue; Zhichao Li; Pikun Cao; Yanting Hu; Hongchao Cai; Zhigang Wei; Xin Ye
Journal:  Thorac Cancer       Date:  2022-08-01       Impact factor: 3.223

8.  The Effect of Microwave Ablation Combined with Anti-PD-1 Monoclonal Antibody on T Cell Subsets and Long-Term Prognosis in Patients Suffering from Non-Small-Cell Lung Cancer.

Authors:  Wenbo Yu; Jiewei Sun; Tao Wang; Yanan Du
Journal:  Comput Math Methods Med       Date:  2022-09-26       Impact factor: 2.809

9.  Percutaneous local tumor ablation vs. stereotactic body radiotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Dongjie Chen; Man Zhao; Xiaoyong Xiang; Jun Liang
Journal:  Chin Med J (Engl)       Date:  2022-07-14       Impact factor: 6.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.